Back to Search
Start Over
β-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients
- Source :
- Oral diseasesREFERENCES. 28(6)
- Publication Year :
- 2021
-
Abstract
- OBJECTIVES The myeloid-derived suppressor cells (MDSCs) frequently have a high expansion in cancer patients. This research explored whether administration of β-glucan could increase anti-tumor immunity in oral squamous cell carcinoma (OSCC) patients. MATERIALS AND METHODS This study evaluated the MDSC level of circulating blood as CD33+ /CD11b+ /HLA-DR-/low by flow cytometry in 30 healthy donors (HDs, group I), in 48 oral squamous cell carcinoma (OSCC) patients before and after 14-day preoperative administration of β-glucan (group II), and in 52 OSCC patients without taking β-glucan (group III). RESULTS A significantly higher mean MDSC level was observed in 100 OSCC patients than in 30 HDs (p
- Subjects :
- Oncology
medicine.medical_specialty
beta-Glucans
CD33
Flow cytometry
03 medical and health sciences
0302 clinical medicine
Immunity
Internal medicine
medicine
Humans
General Dentistry
Glucan
chemistry.chemical_classification
medicine.diagnostic_test
biology
Proportional hazards model
business.industry
Squamous Cell Carcinoma of Head and Neck
Myeloid-Derived Suppressor Cells
Cancer
030206 dentistry
medicine.disease
stomatognathic diseases
Otorhinolaryngology
Integrin alpha M
chemistry
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Myeloid-derived Suppressor Cell
biology.protein
Carcinoma, Squamous Cell
Mouth Neoplasms
business
Subjects
Details
- ISSN :
- 16010825
- Volume :
- 28
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Oral diseasesREFERENCES
- Accession number :
- edsair.doi.dedup.....2d7ff28baf4ff4d1ed17b15f00719b16